November 26, 2015
Amgen’s first Humira biosimilar application for ABP 501 to the FDA
Amgen has filed a Biologics License Application (BLA) with the United States (U.S.) Food and Drug Administration (FDA) for ABP 501,…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Sean E. Harper
November 17, 2015
Amgen showcases abstracts from Imlygic study at 12th International Congress of the Society for Melanoma Research
Amgen will present eight IMLYGIC (talimogene laherparepvec) abstracts, including data from the Phase 3 trial and new data from its Phase 1b combination trial with Merck’s anti-PD-1 therapy, at the 12th International Congress of the Society for Melanoma Research …
September 23, 2015
Phase 3 study of ABP 215 meets its endpoints
Amgen and Allergan plc. announced on Wednesday that a Phase 3 study of biosimilar candidate ABP 215 met its primary…